Table 3.

Quality of life specific to colorectal cancer, depression, perceived diagnostic delay, and trust in the results of any future FOBt among patients with different screening histories

Comparison with screen-detectedComparison with not offered screening
VariablesInterval cancerScreen-detectedUnadjusted difference (95% CIs)PAdjusted differencec (95% CIs)PNot offered screeningDifference (95% CIs)PAdjusted differencec (95% CIs)P
Quality of life (FACT-C)b (0–136)108.26 (18.37; n = 90)116.57 (13.63; n = 94)8.31 (3.43–13.20)<0.0016.16 (0.65–11.66)0.03110.67 (18.53; n = 82)2.41 (−2.65 to 7.47)0.351.70 (−3.67 to 7.07)0.54
Depressiona (0–30)5.23 (4.54; n = 98)3.97 (4.14; n = 105)−1.26 (−0.03 to −2.49)0.05−0.68 (−2.05 to 0.69)0.335.36 (4.72; n = 87)0.14 (−1.15 to 1.42)0.840.39 (−0.97 to 0.74)0.58
Perceived diagnostic delay (n and (%) yes vs. no or not sure)a30 (31)15 (14)OR, 0.37 (0.19–0.75)0.01OR, 0.37 (0.17–0.83)0.0234 (37)OR, 1.33 (0.73–2.44)0.35OR, 1.21 (0.61–2.41)0.58
Trust in the results if were to have an FOB test (1–4)a2.74 (1.06; n = 99)3.84 (0.46; n = 105)1.10 (0.90–1.31)<0.0011.11 (0.87–1.35)<0.0013.60 (0.56; n = 89)0.86 (0.65–1.07)<0.0010.86 (0.63–1.09)<0.001

NOTE: Values are means (values for delay are frequencies and ORs).

  • aMissing data <5%.

  • bMissing data >5%.

  • cAdjusted for age, gender, deprivation, time since diagnosis, receipt of radiotherapy or chemotherapy, and presence of comorbidities.